The obesity duopoly has been pierced as Amgen positions itself to have a drug on the market in a few years. While this adds ...
The market didn't appreciate Amgen 's ( AMGN 1.00%) latest clinical data update, with the biopharma's shares falling more ...
According to phase 2 study, MariTide achieved significant weight loss in individuals with obesity or overweight, with up to ...
Zacks.com on MSN22h
Biotech Stock Roundup: BBIO Stock Up on Drug Approval, SAVA, APLT Plunge on Setbacks & MorePipeline and regulatory updates are in focus in the biotech sector. Among these, BridgeBio Pharma, Inc. BBIO gained on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback